Lanean...
Clostridioides difficile-induced diarrhoea following dasatinib therapy
Dasatinib, an oral tyrosine kinase inhibitor, is approved for therapy of chronic myeloid leukaemia (CML). Common adverse effects of this therapy include myelosuppression, fluid retention and diarrhoea. However, Clostridioides difficile infections (CDIs) in the context of dasatinib therapy, without a...
Gorde:
| Argitaratua izan da: | BMJ Case Rep |
|---|---|
| Egile Nagusiak: | , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
BMJ Publishing Group
2021
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7813327/ https://ncbi.nlm.nih.gov/pubmed/33462050 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bcr-2020-239394 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|